Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Konkret geht es um den Diabetes-Patienten mit kardiovaskulären Erkrankungen oder Risiken, die Herzinsuffizienz sowie die kardiovaskuläre Primär- und Sekundärprävention. Sind Sie hier schon auf dem neuesten Stand? Unsere Experten beleuchten, wo und warum das bisherige Procedere geändert werden soll und was in der Praxis sinnvoll ist. Holen Sie sich Ihr Update und 2 CME-Punkte beim MMW-Webinar am 24. April von 17.30 bis 19 Uhr. 
Erweiterte Suche
Anmelden
nach oben
BMC Infectious Diseases
Erschienen in: BMC Infectious Diseases 1/2022

Open Access 01.12.2022 | Correction

Correction to: Molecular identification and antifungal susceptibility profile of yeast from vulvovaginal candidiasis

verfasst von: Yu Shi, Yuxia Zhu, Shangrong Fan, Xiaoping Liu, Yiheng Liang, Yingying Shan

Erschienen in: BMC Infectious Diseases | Ausgabe 1/2022

download
DOWNLOAD
print
DRUCKEN
insite
SUCHEN
Hinweise
Yu Shi and Yuxia Zhu contributed equally to this work
The original article can be found online at https://​doi.​org/​10.​1186/​s12879-020-04985-w.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Correction to: BMC Infectious Diseases (2020) 20:287 https://​doi.​org/​10.​1186/​s12879-020-04985-w

Following publication of the original article [1], the authors identified an error in Table 3. The correct table (Table 3) is given in this erratum and the original article has been corrected.
Table 3
In vitro antifungal susceptibility of 1844 clinical isolates of Candida species as determined by the CLSI method
Candida species (n)
Antifungal agents
 
BUC
CLO
FLC
ITC
MIC
TEC
VRC
C. lusitaniae, n = 1
Range
0.03
0.03
0.125
0.03
0.03
0.03
0.03
C. Fabianii, n = 3
Range
0.03–0.25
0.03–0.06
0.5–1
0.03–0.25
0.125–1
0.03
0.03
MIC50
0.125
0.03
0.5
0.06
0.125
0.03
0.03
MIC90
0.25
0.06
1
0.25
1
0.03
0.03
Trichosporon asahii, n = 1
Range
0.03
0.03
0.25
0.03
0.06
0.03
0.03
Rhodotorula, n = 3
Range
0.03–0.5
0.03–1
4–128
0.03–8
0.25–8
0.03–0.5
0.03–1
MIC50
0.06
0.06
64
2
1
0.06
0.03
MIC90
0.5
1
128
8
8
0.5
1
Kodamaea ohmeri, n = 2
Range
0.125–0.5
0.03
0.25–2
0.125–0.25
0.25–0.5
0.03
0.03
MIC50
0.125
0.03
0.25
0.125
0.25
0.03
0.03
MIC90
0.5
0.03
2
0.25
0.5
0.03
0.03
Issatchenkia terricola, n = 2
Range
1–4
0.06–0.125
32–64
0.25–0.5
0.5
0.25
0.25
MIC50
1
0.06
32
0.25
0.5
0.25
0.25
MIC90
4
0.125
64
0.5
0.5
0.25
0.25
Torulaspora pretoriensis, n = 1
Range
0.25
0.03
8
0.5
0.5
0.125
0.125
ATCC90028*
Range
0.015–0.5
0.015–0.5
0.125–2
0.015–4
0.008–0.015
0.015–32
0.015–8
GM
0.04
0.03
0.21
0.08
0.06
0.03
0.03
MIC90
0.125
0.03
0.5
0.25
0.015
0.03
0.03
Candida species (n)
Antifungal agents
  
AmB
FLU
NYS
TEB
AFG
CFG
MFG
C. albicans
n = 1272
Range
0.015–32
0.03–128
0.03–32
0.03–256
0.008–0.5
0.008–0.5
0.008–0.5
 
GM
0.22
0.70
1.60
45.11
0.015
0.1
0.03
 
MIC90
0.5
4
8
256
0.03
0.25
0.25
 
R
 
3.3%
  
0
0
0
C. africana
n = 49
Range
0.03–32
0.06–8
0.125–4
0.25–256
0.008–0.03
0.015–0.5
0.008–0.5
 
GM
0.08
0.68
0.5
17.31
0.01
0.06
0.02
 
MIC90
1
2
4
128
0.015
0.25
0.06
C. dubliniensis
n = 1
Range
0.06
0.06
0.25
16
0.008
0.015
0.008
C. glabrata
n = 267
Range
0.03–2
0.06–16
0.03–32
0.25–256
0.008–0.5
0.008–0.5
0.008–0.5
 
GM
0.29
0.18
3.39
26.62
0.03
0.11
0.05
 
MIC90
1
1
8
256
0.06
0.25
0.25
 
R
 
0
  
0
0
0
C. nivariensis
n = 9
Range
0.06–2
0.125–4
0.5–4
1–256
0.015–0.06
0.08–0.5
0.015–0.5
 
MIC50
0.06
0.5
1
128
0.06
0.25
0.015
 
MIC90
2
2
4
256
0.06
0.5
0.5
C. bracarensis
n = 2
Range
0.06–1
0.125–2
0.25–8
8–256
0.015–0.03
0.125–0.5
0.015–0.5
 
MIC50
0.06
0.125
0.25
8
0.015
0.125
0.015
 
MIC90
1
2
8
256
0.03
0.5
0.5
C. parapsilosis
n = 76
Range
0.03–2
0.125–8
0.03–32
0.25–256
0.008–1
0.008–1
0.008–1
 
GM
0.19
0.14
0.59
0.62
0.69
0.60
0.54
 
MIC90
1
0.125
4
32
0.5
0.5
0.5
 
R
 
0
  
5.2%
5.2%
1.3%
C. metapsilosis
n = 20
Range
0.015–0.5
0.125–4
0.06–4
0.25–256
0.015–0.5
0.008–0.5
0.015–1
 
GM
0.10
0.177
0.46
2.17
0.17
0.17
0.39
 
MIC90
0.5
1
4
256
0.25
0.25
0.5
Candida species (n)
Antifungal agents
  
AmB
FLU
NYS
TEB
AFG
CFG
MFG
C. orthopsilosis
n = 6
Range
0.06–0.25
0.125–2
0.06–8
0.25–128
0.008–1
0.015–1
0.008–0.5
 
MIC50
0.125
1
0.5
64
0.08
0.30
0.25
 
MIC90
0.25
2
8
128
1
1
0.5
C. tropicalis
n = 61
Range
0.03–1
0.125–32
0.03–8
0.25–256
0.015–0.125
0.008–0.5
0.008–0.5
 
GM
0.19
0.23
0.54
60.02
0.03
0.24
0.04
 
MIC90
0.5
1
4
256
0.06
0.5
0.5
 
R
 
1.8%
  
0
0
0
C. krusei
n = 54
Range
0.03–1
0.125–32
0.03–4
16–256
0.015–0.5
0.008–1
0.008–0.5
 
GM
0.43
4.2
0.32
75.66
0.08
0.08
0.15
 
MIC90
1
16
1
256
0.125
0.5
0.25
 
R
 
2.9%
  
0
1.85%
0
Saccharomyces cerevisiae
n = 12
Range
0.03–4
0.06–8
0.125–32
0.25–256
0.015–0.5
0.08–0.5
0.015–0.5
 
GM
0.18
0.21
0.78
53.20
0.14
0.10
0.18
 
MIC90
1
1
8
256
0.5
0.25
0.25
C. guilliermondii
n = 2
Range
0.06–0.5
0.125–0.25
0.25–0.5
64–128
0.015–0.25
0.25–0.5
0.015–0.25
 
MIC50
0.06
0.125
0.25
64
0.015
0.25
0.015
 
MIC90
0.5
0.25
0.5
128
0.25
0.5
0.25
 
R
 
0
  
0
0
0
C. lusitaniae
n = 1
Range
0.125
0.125
0.25
0.25
0.03
0.25
0.015
C. fabianii
n = 3
Range
0.06–0.25
0.125
0.25
128
0.015–0.03
0.015–0.25
0.015–0.06
 
MIC50
0.06
0.125
0.25
128
0.015
0.015
0.03
 
MIC90
0.25
0.125
0.25
128
0.03
0.25
0.06
Trichosporon asahii
n = 1
Range
0.125
1
0.25
128
0.015
0.5
0.015
Rhodotorula
n = 3
Range
0.03–0.5
0.125
0.06–0.125
8–256
0.06–0.5
0.25–0.5
0.25–0.5
 
MIC50
0.03
0.125
0.06
8
0.06
0.25
0.25
 
MIC90
0.5
0.125
0.125
256
0.5
0.5
0.5
Kodamaea ohmeri
n = 2
Range
0.125–1
0.125
0.5
128
0.015
0.125–0.25
0.015–0.03
 
MIC50
0.125
0.125
0.5
128
0.015
0.125
0.015
 
MIC90
1
0.125
0.5
128
0.015
0.25
0.03
Issatchenkia terricola
n = 2
Range
0.125–0.5
8
0.5
128–256
0.06
0.06
0.08
 
MIC50
0.125
8
0.5
128
0.06
0.06
0.08
 
MIC90
0.5
8
0.5
256
0.06
0.06
0.08
Torulaspora pretoriensis
n = 1
Range
0.125
0.125
0.25
16
0.015
0.125
0.015
ATCC90028a
Range
0.03–2
0.125–8
0.25–16
1–256
0.008–0.015
0.015–0.5
0.008–0.015
 
GM
0.22
0.64
1.31
88.22
0.01
0.09
0.01
 
MIC90
1
2
8
256
0.015
0.5
0.015
GM geometry mean, BUC butoconazole, CLO Clotrimazole, FLC Fluconazole, ITC Itraconazole, VRC Voriconazole, MIC Miconazole, TEC Terconazole, AmB Amphotericin B, FLU Flucytosine, NYS Nystatin, TEB Terbinafine, AFG Anidulafungin, CFG Caspofungin, MFG Micafungin
aATCC90028 was tested 57 times
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://​creativecommons.​org/​licenses/​by/​4.​0/​. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
download
DOWNLOAD
print
DRUCKEN
Literatur
1.
Metadaten
Titel
Correction to: Molecular identification and antifungal susceptibility profile of yeast from vulvovaginal candidiasis
verfasst von
Yu Shi
Yuxia Zhu
Shangrong Fan
Xiaoping Liu
Yiheng Liang
Yingying Shan
Publikationsdatum
01.12.2022
Verlag
BioMed Central
Erschienen in
BMC Infectious Diseases / Ausgabe 1/2022
Elektronische ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-021-06601-x

Weitere Artikel der Ausgabe 1/2022

BMC Infectious Diseases 1/2022 Zur Ausgabe

Research

Durable reduction of Clostridioides difficile infection recurrence and microbiome restoration after treatment with RBX2660: results from an open-label phase 2 clinical trial

Research

Metrics of sexual behavior stigma among cisgender men who have sex with men in Mexico: exploratory and confirmatory factor analyses

Research

Monocyte distribution width as a novel sepsis indicator in COVID-19 patients

Research article

Peripherally inserted central catheters have a protective role and the effect of fluctuation curve feature in the risk of bloodstream infection compared with central venous catheters: a propensity-adjusted analysis

Research article

Bacteremia detection from complete blood count and differential leukocyte count with machine learning: complementary and competitive with C-reactive protein and procalcitonin tests

Research

Epidemiology of recurrent pulmonary tuberculosis by bacteriological features of 100 million residents in China

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

23.04.2024 | Ablationstherapie | Nachrichten

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

23.04.2024 | Prävention und Rehabilitation in der Kardiologie | Nachrichten

Europäische Ernährungsgewohnheiten: Das sind die häufigsten Fehler

23.04.2024 | DGIM 2024 | Kongressbericht | Nachrichten

Drei Mythen bei der Antibiotikatherapie

23.04.2024 | Operationsvorbereitung | Nachrichten

Mehr Schaden als Nutzen durch präoperatives Aussetzen von GLP-1-Agonisten?
weitere anzeigen

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise